Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity

NCT07665879 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07665879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07665879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Eloralintide on Insulin Sensitivity and Metabolism in Adult Participants With Overweight or Obesity
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Recruiting
Start date
June 24, 2026
Completion date
August 31, 2027
Enrollment
115 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight